The ‘My Signals‘ resource from NIHR is a new feature enabling health service users and staff to highlight NIHR research that is important to them. In this update a member of the public highlights the project on self-monitoring of warfarin as making an impact on the care of her husband. HERU were involved in the health economics component of the research.
Elsewhere on the page there is a link to a feature on research about managing the obesity of men. This is a research summary rather than a ‘My Signals’ page but does feature the HTA on the management of obesity in men that HERU were involved in.
The Office of Health Economics (OHE) in collaboration with Curtin University and King’s College London, has been awarded a research grant from the EuroQol Research Foundation to compare the sensitivity and responsiveness of the EQ-5D-3L and EQ-5D-5L instruments in a large cohort of cancer patients.
The National Institute for Health and Care Excellence (NICE) have issued a position statement on the use of the EQ-5D-5L valuation set. The statement recommends not using the 5L valuation set for evidence submissions to NICE that use cost-utility analyses. Preference should be given to the EQ-5D-3L valuation set. The full statement gives more detail on the decision from the NICE Decision Support Unit.
The Getting It Right First Time (GIRFT) aims to aims to bring about higher-quality care in hospitals, at lower cost, by reducing unwanted variations in services and practices. The programme is being rolled out across the English NHS and this report from the King’s Fund offers a summary and assessment of the programme.
Timmons, N. (2017) Tackling variations in clinical care: assessing the Getting It Right First Time (GIRFT) programme, London: King’s Fund.
Scottish Health Innovations Ltd (SHIL) have published a short blog post on innovation in healthcare. The post includes a list of the innovations likely to transform healthcare in the next few years. SHIL is an organisation that works in partnership with NHS Scotland to identify, protect, develop and commercialise new innovations from healthcare professionals.
The National Institute for Health and Care Excellence (NICE) have published guidance on Collagenase clostridium histolyticum for treating Dupuytren’s contracture [TA459]. The treatment is recommended only under specific circumstances while an on-going trial is conducted. HERU staff contributed to the evidence for the development of the guidance.
The Mesh Oversight Group Report for NHS England has been published. The report follows on from the Mesh Working Group Interim Report of December 2015. Both reports are about vaginal mesh implants used to treat stress urinary incontinence (SUI) and pelvic organ prolapse (POP) in women, and this report set out the actions that have been taken to meet the recommendations in the Interim Report. The report also summarises resent research on mesh implants and the implications of the research. This includes the Glazener study that HERU staff were involved in.
In Scotland, a review is underway on the safety of mesh implants following publication of the Scottish Independent Review of the use, safety and efficacy of transvaginal mesh implants in the treatment of stress urinary incontinence and pelvic organ prolapse in women.